New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 18, 2014
16:03 EDTQGENQIAGEN receives FDA approval of artus CMV RGQ MDx kit
QIAGEN N.V. announced that its artus CMV RGQ MDx Kit for human cytomegalovirus, or CMV, has been approved by the FDA under a full premarket approval, or PMA. The test is the only FDA-approved PCR-based assay optimized for low- to mid-throughput testing of CMV. With a turn-around time of approximately three hours, the assay provides faster results than other PMA approved tests. artus CMV RGQ MDx runs on QIAGEN's Rotor-Gene Q MDx real-time PCR platform, which was cleared by the FDA in 2012 and is a member of the QIAsymphony modular family of automated instruments.
News For QGEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 18, 2014
06:21 EDTQGENQIAGEN downgraded to Sell from Neutral at Goldman
Goldman downgraded QIAGEN to Sell based on a mixed growth outlook for new products and the dilutive impact on the core franchise value from M&A. Price target lowered to $19 from $21.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use